Rigel Pharmaceuticals
RIGL
136 hedge funds and large institutions have $316M invested in Rigel Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 14 closing their positions.
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
24% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 37
15% more capital invested
Capital invested by funds: $276M → $316M (+$40.3M)
4% more funds holding
Funds holding: 131 → 136 (+5)
0.03% more ownership
Funds ownership: 8.8% → 8.83% (+0.03%)
82% less call options, than puts
Call options by funds: $16K | Put options by funds: $89K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.67M |
| 2 |
Renaissance Technologies
New York
|
+$2.23M |
| 3 |
Morgan Stanley
New York
|
+$2.11M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.9M |
| 5 |
Millennium Management
New York
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.7M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.35M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.33M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.02M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.01M |
RIGL Hedge Fund Activity: Q4 2019 in Review
136 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2019, worth a combined $316M — up 15% from $276M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RIGL positions and 14 closed out — a net gain of 6 holders — while 46 added to existing stakes and 37 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $2.67M. The largest seller was Wellington Management Group, cutting an estimated $10.7M.
- 136 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2019, up from 131 in Q3 2019.
- Funds reported $316M of Rigel Pharmaceuticals stock for Q4 2019, up 15% quarter-over-quarter.
- 20 funds opened new Rigel Pharmaceuticals positions in Q4 2019 and 14 closed out, a net change of +6 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2019 was Rock Springs Capital Management, an estimated $2.67M added.
- The largest Rigel Pharmaceuticals seller in Q4 2019 was Wellington Management Group, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2019.